iCardiac adds $2m to series A:
This article was originally published in Clinica
Executive Summary
Rochester, New York-based iCardiac Technologies has brought the total raised in a series A financing to $4m, after receiving an additional $2m in an investment round led by Advantage Capital Partners and Stonehenge Capital Company. The proceeds will be used "to meet the increased interest in its technology by the pharmaceutical and biotechnology industries", says iCardiac's CEO, Mikael Totterman. The company is developing cardiac safety analysis technologies that can be used for assessing the safety profile of cardiac drugs, as well as for ECG-based cardiac diagnostic and medical device applications.